![](https://investorshub.advfn.com/uicon/607320.png?cb=1602587228)
Monday, April 19, 2021 10:31:47 AM
Post sites article in Nature (journal) that states several "substances" with very low SI showed "little" effect on virus replication OR showed SEVERE ADVERSE EFFECT in human patients....
1. WHY WOULDN"T THEY SHOW "LITTLE" effect...THEY HAD VERY LOW SI SCORES!!! IN FACT, All these "Substances" COMBINED did not match BRILACIDIN'S SI SCORE *426*. TO COMPARE THESE SUBSTANCES TO OR ANY SUBSTANCE in competition with BRILACIDIN...the substance being compared (which there are NONE) would be "SI" Score of 426...THERE ARE NO OTHERS! So, the comparative statement is comparing rotten apples to juicy oranges.
2. AGAIN...BRILACIN's SI's 426 SCORE is greater than ALL THOSE SUBSTANCES SI SCORE COMBINED and they showed "Little effect", therefore it is reasonable to expect Brilacidin, with 10X SI score of substances cited,...to show SIGNIFICANTLY MORE EFFECT on Covid viral suppression.
3. SAE COMPARISON? as is noted in quote...those OTHER SUBSTANCES "...led to SAE (severe adverse events and side effects) in human patients."...OK...but BRILACIDIN throughout PHASE II Clinical Trials for 5 Different Indications...BRILACIDIN has NEVER CAUSED a single SAE.
So what these "other" substances do it totally irrelevant to Brilacidin.
Quote:
"...several substances like Remdesivir, Lopinavir and Chloroquine were reported to repress viral replication in vitro. However, these compounds showed little effect on virus replication or led to severe adverse side effects in human patients." Bottom line: is that the
in vitro assays in cells did not predict clinical behavior.
Conclusion:
SUBSTANCES WITH Small SI SCORES showed small SUPRESSION of VIRAL SUPPRESSION in Clinical Trials...therefore Substances (Brilacidin) with EXTREMELY HIGH (HIGHEST) SI SCORE OF POTENTIAL THERAPEUTICS ... will likely demonstrate in Clinical Trials EXTREMELY HIGH VIRAL SUPPRESSION in current clinical trials...compared to the substances sited.
Thank you for providing a post to further demonstrate the GREAT POTENTIAL of BRILACIDIN vs. Covid-19 IMO soon to be demonstrated in the current Clinical Trials!
Leo Ehrilich Quote "If Brilacidin goes on to realize its promise as a broad spectrum antiviral, the potential benefits to patients and shareholders for this drug would likely be greater than I or anyone could have ever imagined.”
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM